Oral contraceptives: therapeutics versus adverse reactions, with an outlook for the future. II.
D000568:Amenorrhea / Q000139:chemically induced; D001798:Blood Proteins / Q000378:metabolism; D001943:Breast Neoplasms / Q000139:chemically induced; D050260:Carbohydrate Metabolism; D002584:Cervix Uteri / Q000473:pathology; D056486:Chemical and Drug Induced Liver Injury; D002784:Cholesterol / Q000097:blood; D003276:Contraceptives, Oral / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D006965:Hyperplasia / Q000139:chemically induced; D006973:Hypertension / Q000139:chemically induced; D007565:Jaundice / Q000139:chemically induced; D007775:Lactation Disorders / Q000139:chemically induced; D050356:Lipid Metabolism; D009369:Neoplasms / Q000139:chemically induced / Q000473:pathology; D011247:Pregnancy; D011506:Proteins / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
D001798:Blood Proteins; D003276:Contraceptives, Oral; D011506:Proteins; D014280:Triglycerides; D002784:Cholesterol